Malvin Driver, MD
Ophthalmology · Ellsworth
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Cec LLC · Shah Eye Center PA
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Driver’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Texas E7897Physician License · since 1977 · expires 2027-11-30ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$587,212
Medicare paid this office $587,212 for 427 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 46 | $196,011 | None |
| Injection, aflibercept, 1 mg | 62 | $176,063 | None |
| Injection of drug into eye | 130 | $35,081 | $91 |
| Imaging of retina | 417 | $27,629 | $30 |
| Return visit (30+ min) | 236 | $24,921 | $90 |
See all 12 services
| Injection, faricimab-svoa, 0.1 mg | 46 | $196,011 | None |
| Injection, aflibercept, 1 mg | 62 | $176,063 | None |
| Injection of drug into eye | 130 | $35,081 | $91 |
| Imaging of retina | 417 | $27,629 | $30 |
| Return visit (30+ min) | 236 | $24,921 | $90 |
| Destruction of growth of retina using a laser | 31 | $16,708 | $371 |
| Established patient complete exam of visual system | 114 | $9,540 | $80 |
| New patient visit (45+ min) | 70 | $8,567 | $122 |
| Short return visit (20+ min) | 71 | $5,495 | $69 |
| Compounded drug, not otherwise classified | 37 | $3,685 | None |
| Short return visit | 48 | $2,660 | $44 |
| Established patient problem focused exam of visual system | 16 | $1,036 | $65 |
Who their Medicare patients are
427 Original Medicare patients in 2024. Average age 78 · Women 60% · Also on Medicaid 7% · Health risk score 1.20. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 37% · Coronary heart disease 28% · Chronic kidney disease 25% · Heart failure 21% · Atrial fibrillation 20% · Cancer 18% · Depression 17% · COPD 14% · Dementia 7% · Stroke 7%.
The office billed $1,868,679, Medicare allowed $747,247 and paid $587,212; for 10,182 services of 24 kinds; $448,399 of it was for drugs given in the office and $138,812 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 427 | 10,182 | 78 | 1.20 | $1,868,679 | $587,212 |
| 2023 | 300 | 3,501 | 77 | 1.18 | $661,552 | $206,241 |
| 2021 | 412 | 1,770 | 78 | 1.56 | $487,872 | $80,688 |
| 2020 | 616 | 1,810 | 76 | 1.63 | $478,737 | $130,081 |
| 2019 | 79 | 283 | 70 | 1.43 | $128,547 | $54,372 |
| 2018 | 65 | 224 | 69 | 1.77 | $136,563 | $36,810 |
| 2017 | 38 | 104 | 74 | 1.66 | $33,266 | $11,342 |
| 2014 | 231 | 1,746 | 76 | 2.07 | $353,258 | $247,383 |
| 2013 | 339 | 3,567 | 75 | 1.78 | $902,188 | $676,749 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Injection, faricimab-svoa, 0.1 mg | 18 | $67,877 | None |
| Injection, aflibercept, 1 mg | 19 | $59,729 | None |
| New patient visit (45+ min) | 185 | $21,058 | $114 |
| Established patient complete exam of visual system | 140 | $18,719 | $95 |
| Imaging of retina | 287 | $13,358 | $30 |
| Injection of drug into eye | 46 | $10,451 | $91 |
| Destruction of growth of retina using a laser | 14 | $6,354 | $397 |
| Short return visit | 12 | $613 | $44 |
| Photography of the retina | 18 | $497 | $26 |
2021: 11 services
| Injection of drug into eye | 124 | $22,451 | $62 |
| Imaging of retina | 390 | $10,564 | $15 |
| Short return visit (20+ min) | 95 | $10,055 | $50 |
| Established patient complete exam of visual system | 251 | $9,382 | $35 |
| Return visit (30+ min) | 95 | $5,740 | $53 |
| Destruction of growth of retina using a laser | 16 | $5,677 | $355 |
| New patient visit (45+ min) | 20 | $1,962 | $98 |
| New patient complete exam of visual system | 23 | $1,430 | $62 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 13 | $490 | $33 |
| Established patient problem focused exam of visual system | 11 | $237 | $22 |
| Photography of the retina | 16 | $213 | $13 |
2020: 8 services
| Established patient complete exam of visual system | 527 | $39,306 | $70 |
| Injection of drug into eye | 129 | $18,950 | $75 |
| Destruction of growth of retina using a laser | 27 | $13,215 | $389 |
| Imaging of retina | 451 | $13,068 | $21 |
| Established patient problem focused exam of visual system | 95 | $5,305 | $48 |
| New patient complete exam of visual system | 49 | $4,685 | $96 |
| Injection, bevacizumab, 10 mg | 27 | $2,918 | None |
| Photography of the retina | 12 | $385 | $32 |
2019: 5 services
| Established patient complete exam of visual system | 39 | $5,055 | $87 |
| Injection of drug into eye | 12 | $3,115 | $84 |
| New patient visit (45+ min) | 27 | $2,723 | $101 |
| New patient complete exam of visual system | 13 | $1,294 | $100 |
| Imaging of retina | 20 | $1,258 | $31 |
2018: 3 services
| New patient visit (45+ min) | 28 | $3,099 | $111 |
| Established patient complete exam of visual system | 17 | $3,050 | $90 |
| Imaging of retina | 12 | $983 | $30 |
2017: 1 service
| New patient complete exam of visual system | 30 | $2,765 | $92 |
2014: 10 services
| Injection, ranibizumab, 0.1 mg | 39 | $108,747 | None |
| Injection, aflibercept, 1 mg | 15 | $27,530 | None |
| Injection of drug into eye | 93 | $21,718 | $71 |
| Established patient complete exam of visual system | 174 | $17,397 | $83 |
| Destruction of growth of retina using a laser | 20 | $11,397 | $393 |
| Injection, bevacizumab, 10 mg | 82 | $10,003 | None |
| Imaging of retina | 119 | $9,000 | $32 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 53 | $8,355 | $75 |
| Photography of the retina | 75 | $4,205 | $50 |
| Established patient problem focused exam of visual system | 30 | $2,175 | $54 |
2013: 12 services
| Injection, ranibizumab, 0.1 mg | 65 | $293,659 | None |
| Injection, aflibercept, 1 mg | 39 | $176,030 | None |
| Injection of drug into eye | 128 | $42,063 | $73 |
| Established patient complete exam of visual system | 274 | $32,623 | $85 |
| Imaging of retina | 184 | $19,108 | $33 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 89 | $15,167 | $77 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $14,174 | $1,090 |
| Injection, bevacizumab, 10 mg | 79 | $10,736 | None |
| Photography of the retina | 115 | $6,797 | $50 |
| Destruction of growth of retina using a laser | 15 | $6,785 | $399 |
| Established patient problem focused exam of visual system | 41 | $3,401 | $62 |
| New patient complete exam of visual system | 20 | $1,929 | $96 |
Medicaid work
$11,260 in 2021
Medicaid paid $11,260 for 456 billed services this clinician did in 2021, up to 45 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 117 | $5,084 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 212 | $2,908 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 76 | $2,500 |
| Short return visit (20+ min) | 51 | $767 |
| 2021 | 456 | 4 | 45 | $11,260 |
| 2020 | 282 | 5 | 41 | $9,459 |
See the largest Medicaid services in earlier years
2020
| TREATMENT OF RETINAL LESION | 16 | $3,808 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 125 | $1,992 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 32 | $1,991 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 97 | $1,483 |
| DETERMINATION REFRACTIVE STATE | 12 | $186 |
Drugs they prescribed that Part D paid
$14,269
Pharmacies billed $14,269 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 157) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
127 generic and 30 brand-name prescriptions · $14,269 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bromfenac | 29 | $3,652 | $126 |
| Timolol Maleate | 26 | $460 | $18 |
| Dorzolamide-Timolol | 14 | $322 | $23 |
| Ketorolac Tromethamine | 13 | $110 | $8 |
Year by year
| 2024 | 157 | 51 | 0% (0) | 19% | $14,269 |
| 2023 | 46 | 22 | 0% (0) | 28% | $5,710 |
| 2021 | 78 | 31 | None | 55% | $18,958 |
| 2020 | 257 | 62 | 0% (0) | 48% | $35,532 |
| 2019 | 178 | 36 | None | 57% | $28,321 |
| 2018 | 73 | 25 | None | 55% | $8,439 |
| 2017 | 19 | None | None | None | $1,276 |
| 2015 | 19 | None | None | None | $646 |
| 2014 | 70 | 31 | None | None | $3,515 |
| 2013 | 207 | 95 | 9% (18) | 64% | $19,725 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 2 drugs
| Ilevro | 14 | $4,435 | $317 |
| Latanoprost | 13 | $278 | $21 |
2020: 7 drugs
| Combigan | 51 | $11,324 | $222 |
| Rocklatan | 15 | $5,282 | $352 |
| Travoprost | 18 | $2,805 | $156 |
| Latanoprost | 46 | $842 | $18 |
| Dorzolamide-Timolol | 13 | $400 | $31 |
| Dorzolamide | 15 | $287 | $19 |
| Timolol Maleate | 20 | $185 | $9 |
2019: 4 drugs
| Combigan | 26 | $7,073 | $272 |
| Travatan Z | 16 | $4,752 | $297 |
| Latanoprost | 34 | $309 | $9 |
| Timolol Maleate | 16 | $160 | $10 |
2018: 2 drugs
| Combigan | 11 | $1,778 | $162 |
| Latanoprost | 11 | $123 | $11 |
2015: 1 drug
| Latanoprost | 16 | $197 | $12 |
2014: 2 drugs
| Dorzolamide-Timolol | 15 | $524 | $35 |
| Latanoprost | 22 | $256 | $12 |
2013: 5 drugs
| Vigamox | 52 | $5,922 | $114 |
| Nevanac | 30 | $5,609 | $187 |
| Tobramycin-Dexamethasone | 19 | $1,774 | $93 |
| Dorzolamide-Timolol | 16 | $705 | $44 |
| Latanoprost | 18 | $294 | $16 |
Money from drug and device companies
$113 in 2025
| 2025 | 2 | 4 | None | $113 |
| 2024 | 1 | 1 | None | $17 |
| 2023 | 1 | 2 | None | $36 |
| 2020 | 2 | 5 | None | $204 |
| 2019 | 2 | 2 | None | $259 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $66 | 2 payments
|
| Astellas Pharma US | Izervay | $48 | 2 payments
|
See all 4 published payments
| Regeneron Healthcare Solutions | Meals · 2025-12-16 | Eylea Hd | $30 |
| Astellas Pharma US | Meals · 2025-10-14 | Izervay | $29 |
| Astellas Pharma US | Meals · 2025-09-17 | Izervay | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-08-19 | Eylea Hd | $36 |
See earlier years (2024, 2023, 2020, 2019)
2024: $17
| Genentech USA | Vabysmo | $17 | 1 payment
|
2023: $36
| Genentech USA | Vabysmo | $36 | 2 payments
|
2020: $204
| Novartis Pharmaceuticals | Beovu | $179 | 4 payments
|
| TissueTech | Prokera | $25 | 1 payment
|
2019: $259
| Alcon Vision | Constellation | $134 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609800127
- Licence
- KY 52609, TX E7897Texas E7897: Active
- Trained
- College of Physicians and Surgeons (Arkansas), 1973
- Group
- Cec LLC · Shah Eye Center PA
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- IN 300025897, KY 7100593500, TX 127822810
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0108X (207WX0108X)
- Mailing address
- 2191 Nw Military Hwy, San Antonio, TX, 78213
- NPI first listed
- 2006-07-10
- NPI last updated
- 2019-07-05
This is when the NPI record was last certified, not a medical board exam.